Business
BetterLife Pharma Highlights Advantages of BETR-001 - a Potent Neuroplastogen
VANCOUVER, BC - December 4, 2025 (NEWMEDIAWIRE) - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, focused on development of BETR-001, its proprietary non-hallucinogenic deriv...
About this update from Betterlife Pharma Inc.
[{"type":"text","content":"VANCOUVER, BC - December 4, 2025 (NEWMEDIAWIRE) - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD").","length":324,"tagName":"p"},{"type":"text","content":"Following recent news from a Phase 2 trial showing LSD microdosing is ineffective for depression, BetterLife highlights BETR-001's advantages over LSD. BETR-001 remains non-hallucinogenic even at high doses, as shown in our previous publication, and does not induce tolerance with repeated use, meaning that BETR-001 can be dosed on a chronic or repeated basis. Preclinical studies indicate that neuroplastogenic effects require sufficient dosing. Since BETR-001 can be administered at full dose without hallucinations, it maintains its effectiveness following repeated dosing.","length":581,"tagName":"p"},{"type":"text","content":"Dr. Ahmad Doroudian, CEO of BetterLife, commented, "The importance of being able to give full doses of BETR-001 without hallucinations cannot be over-emphasized. Microdosing of psychedelics is often touted as the path forward to avoid the hallucinations of psychedelics full dosing and the need for treatment in specialized clinics with monitoring under special treatment protocols, which require in-clinic time of 8 to 12 hours. BETR-001 overcomes all these hurdles and can be administered at its full effective dose without any hallucinations."","length":556,"tagName":"p"},{"type":"text","content":"Dr. Doroudian further commented, "We are completing the last remaining BETR-001 IND-enabling studies and plan to file the IND and begin human clinical trials by 2H 2026. Our initial scope is to develop BETR-001 for treatment of Traumatic Brain Injury ("TBI"), cluster headaches and migraine. BETR-001 also has potential for treatment of a broad range of psychiatric disorders and they will also be explored as the compound's development life cycle moves forward."","length":487,"tagName":"p"},{"type":"text","content":"About BetterLife Pharma ","length":23,"tagName":"p"},{"type":"text","content":"BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-00...